Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Mixtard 30 InnoLet 100units/ml inj 3ml pre-filled pens
0601012D0BCBDBZ
|
Insulin biphasic isophane (Novo-Nordisk) | Biphasic isophane insulin | Endocrine System | No data available |
|
Mixtard 30 NovoLet 100units/ml suspension for injection
0601012D0BCARBZ
|
Insulin biphasic isophane (Novo-Nordisk) | Biphasic isophane insulin | Endocrine System | No data available |
|
Mixtard 40 NovoLet 100units/ml suspension for injection
0601012D0BCAUBH
|
Insulin biphasic isophane (Novo-Nordisk) | Biphasic isophane insulin | Endocrine System | No data available |
|
Mixtard 40 Penfill 100units/ml inj 3ml cartridges
0601012D0BCBBBK
|
Insulin biphasic isophane (Novo-Nordisk) | Biphasic isophane insulin | Endocrine System | No data available |
|
Mixtard 50 NovoLet 100units/ml suspension for injection
0601012D0BCAVBX
|
Insulin biphasic isophane (Novo-Nordisk) | Biphasic isophane insulin | Endocrine System | No data available |
|
Mixtard 50 Penfill 100units/ml inj 3ml cartridges
0601012D0BCBCBU
|
Insulin biphasic isophane (Novo-Nordisk) | Biphasic isophane insulin | Endocrine System | No data available |
|
Modrenal 120mg capsules
0607030T0BBABAB
|
Modrenal | Trilostane | Endocrine System | No data available |
|
Modrenal 60mg capsules
0607030T0BBAAAA
|
Modrenal | Trilostane | Endocrine System | No data available |
|
MODZ testing strips
0601060D0DXAAA0
|
MODZ (Reagent) | Glucose blood testing reagents | Endocrine System | No data available |
|
Monotard 100units/ml suspension for injection 10ml vials
0601012G0BDABAH
|
Insulin zinc suspension (Novo-Nordisk) | Insulin zinc suspension | Endocrine System | No data available |
|
Myalepta 11.3mg powder for solution for injection vials
0607050A0BBACAC
|
Myalepta | Metreleptin | Endocrine System | No data available |
|
Myalepta 3mg powder for solution for injection vials
0607050A0BBAAAA
|
Myalepta | Metreleptin | Endocrine System | No data available |
|
Myalepta 5.8mg powder for solution for injection vials
0607050A0BBABAB
|
Myalepta | Metreleptin | Endocrine System | No data available |
|
Myglucohealth testing strips
0601060D0CKAAA0
|
Myglucohealth (Reagent) | Glucose blood testing reagents | Endocrine System | No data available |
|
MySugarWatch beta-ketone testing strips
0601060W0BLAAA0
|
MySugarWatch (Reagent) | Ketone blood testing reagents | Endocrine System | No data available |
|
MySugarWatch testing strips
0601060D0FBAAA0
|
MySugarWatch (Reagent) | Glucose blood testing reagents | Endocrine System | No data available |
|
Nalvee 10mg tablets
0604012F0BCAAAA
|
Nalvee | Dydrogesterone | Endocrine System | No data available |
|
Nandrolone 50mg/1ml solution for injection ampoules
0604030L0AAABAB
|
Nandrolone decanoate (Hormone) | Nandrolone decanoate | Endocrine System | No data available |
|
Natrol DHEA 10mg tablets
0604030Q0BGAAAL
|
Natrol DHEA | Prasterone | Endocrine System | No data available |
|
Nature-Throid 130mg (2 grains) tablets
0602010Z0BDACAD
|
Nature-Throid | Levothyroxine sodium and liothyronine | Endocrine System | No data available |
|
Nature-Throid 16.25mg (quarter grain) tablets
0602010Z0BDADAE
|
Nature-Throid | Levothyroxine sodium and liothyronine | Endocrine System | No data available |
|
Nazdol MR 30mg tablets (Consilient Health)
0601021M0BFAAAM
|
Nazdol | Gliclazide | Endocrine System | No data available |
|
Nazdol MR 30mg tablets (Mylan)
0601021M0BFABAM
|
Nazdol | Gliclazide | Endocrine System | No data available |
|
Nazdol MR 30mg tablets (Teva)
0601021M0BFACAM
|
Nazdol | Gliclazide | Endocrine System | No data available |
|
Neofordex 40mg tablets
0603020G0BHAACJ
|
Neofordex | Dexamethasone | Endocrine System | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.